{"id":"askc202-limertinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ASKC202 bridges EGFR and c-MET signaling pathways to prevent compensatory activation, while limertinib irreversibly inhibits mutant EGFR including T790M resistance mutations. This dual approach targets both primary EGFR-driven proliferation and c-MET-mediated escape mechanisms that drive acquired resistance in advanced lung cancer.","oneSentence":"ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:41.054Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors"}]},"trialDetails":[{"nctId":"NCT05306132","phase":"PHASE1","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067","status":"RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2022-08-08","conditions":"Advanced Solid Tumor","enrollment":150},{"nctId":"NCT07109531","phase":"PHASE3","title":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","startDate":"2025-08-31","conditions":"Locally Advanced or Metastatic NSCLC","enrollment":286}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASKC202+ Limertinib","genericName":"ASKC202+ Limertinib","companyName":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","companyId":"jiangsu-aosaikang-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASKC202 is a bispecific antibody targeting EGFR and c-MET, combined with limertinib, a third-generation EGFR tyrosine kinase inhibitor, to overcome resistance in EGFR-mutant lung cancer. Used for EGFR-mutant non-small cell lung cancer with acquired resistance to prior EGFR inhibitors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}